The Effect of Centchroman on Mastalgia

Abstract

Mastalgia, a prevalent issue among women aged 20-40, affects quality of life. Although 2% to 7% of those with mastalgia are diagnosed with breast cancer, most cases involve benign conditions. Effective management typically begins with nonmedical interventions such as reassurance and supportive bras, which alleviate concerns for 75%-80% of patients. For those needing medical treatment, various drugs are used, including Centchroman (Ormeloxifene), a selective estrogen receptor modulator (SERM) with minimal side effects. This study assesses the efficacy of Ormeloxifene in managing mastalgia using the Visual Analogue Scale (VAS) to measure pain regression and predict healing time. The study's objectives include analyzing the demographic profile of mastalgia patients, applying ‘triple assessment’ (Clinical Breast Examination, Breast Imaging, and Fine Needle Aspiration Cytology) for diagnosis, and comparing the effectiveness of vitamin E and Centchroman in improving quality of life. Conducted over nine months at MR Bangur Hospital, Kolkata, the study involved 104 women aged 18-50 years. Participants were randomly assigned to receive either Centchroman or vitamin E and recorded demographic data, breast pain characteristics, and treatment outcomes using the VAS score. Results indicated a higher prevalence of mastalgia among women aged 20 to 39, with significant demographic and socioeconomic factors influencing its occurrence. Both Centchroman and vitamin E significantly reduced pain scores, with Centchroman showing greater efficacy and cost-effectiveness. The study underscores the need for further research to validate these findings and optimize mastalgia management protocols, highlighting Centchroman as a valuable treatment option with minimal side effects.